The coagulation cascade is the series of enzyme reactions that turns flowing blood into a stable clot after vessel injury. It matters because effective clotting prevents dangerous blood loss, while excessive clotting can block blood vessels and damage organs. Medical students study the cascade to understand bleeding disorders, thrombosis, and the action of common drugs such as heparin and warfarin.
The pathway is traditionally divided into intrinsic, extrinsic, and common branches to make the sequence easier to learn.
The extrinsic pathway begins when tissue factor is exposed after injury and activates factor VII, while the intrinsic pathway starts with contact activation involving factors XII, XI, IX, and VIII. Both pathways converge by activating factor X, which converts prothrombin to thrombin in the common pathway. Thrombin then converts fibrinogen to fibrin, and factor XIII cross-links fibrin to form a stable clot.
Laboratory tests such as PT and aPTT help identify which part of the cascade may be impaired.
Understanding Coagulation Cascade
Most clotting factors circulate as inactive proteins called zymogens. This is a safety feature. If they were active all the time, blood could clot inside healthy vessels.
Injury exposes collagen and tissue surfaces that are normally hidden. Platelets stick to these surfaces, change shape, and release chemical signals. They form an early platelet plug.
Activated platelets provide a phospholipid surface where many clotting reactions happen quickly. Calcium ions are needed for several of these proteins to attach to that surface. This explains why a shortage of platelets causes a different kind of bleeding from a shortage of a clotting factor.
Thrombin is the central amplifier of clotting. A small initial signal can produce a much larger burst of thrombin on the platelet surface. Thrombin strengthens the response by activating platelets and several helper factors.
It then changes soluble fibrinogen into long fibrin strands. The strands weave through the platelet plug like a net and trap red blood cells. Factor thirteen makes links between fibrin strands, so the clot can resist blood flow.
After the vessel begins to repair, platelets pull on the fibrin network. This clot retraction brings damaged edges closer together. Later, plasmin breaks down fibrin so the clot does not remain after healing.
Clotting must stay local. Healthy vessel lining cells make substances that discourage platelet activation and limit enzyme activity. Antithrombin blocks important active factors, especially thrombin and factor ten a.
Protein C and protein S reduce the activity of factors five a and eight a. Tissue factor pathway inhibitor slows the early tissue factor signal. Problems in these control systems can cause thrombosis, meaning a clot forms where it is not needed.
A clot in a leg vein can travel to the lungs. A clot in an artery can cut off oxygen to heart muscle or brain tissue.
The liver makes most clotting factors, and vitamin K is needed to make several of them work properly. Liver disease, poor vitamin K absorption, and some medicines can therefore increase bleeding risk.
When learning the cascade, focus first on the job of each stage rather than memorising a long list of numbers. Learn which factors act as enzymes, which act as helpers, and where platelets, calcium, and phospholipid surfaces fit in. Laboratory results become easier to understand when linked to a patient story.
A prolonged PT can occur with warfarin use, vitamin K deficiency, or reduced production of factors by the liver. A prolonged aPTT may point toward low factor eight or factor nine, as in forms of haemophilia.
Some people with an abnormal aPTT do not bleed because they have a lupus anticoagulant, an antibody that interferes with the test but can be linked with clotting in the body. This shows why a test result needs clinical context.
Key Facts
- Extrinsic pathway: Tissue factor + factor VIIa activates factor X.
- Intrinsic pathway sequence: XII -> XI -> IX, with VIIIa helping IXa activate X.
- Common pathway: Xa + Va converts factor II to IIa, and IIa converts factor I to fibrin.
- Factor II = prothrombin, factor IIa = thrombin, factor I = fibrinogen.
- Stable clot formation: fibrin + factor XIIIa cross-linking.
- PT mainly assesses extrinsic and common pathways, while aPTT mainly assesses intrinsic and common pathways.
Vocabulary
- Tissue factor
- Tissue factor is a membrane protein exposed by damaged tissue that starts the extrinsic coagulation pathway.
- Thrombin
- Thrombin is the active enzyme form of factor II that converts fibrinogen into fibrin and amplifies clotting.
- Fibrin
- Fibrin is the insoluble protein mesh that stabilizes a blood clot.
- Prothrombin time
- Prothrombin time is a lab test that evaluates the extrinsic and common coagulation pathways.
- Activated partial thromboplastin time
- Activated partial thromboplastin time is a lab test that evaluates the intrinsic and common coagulation pathways.
Common Mistakes to Avoid
- Confusing the intrinsic and extrinsic starting points, because intrinsic starts with contact activation inside the blood while extrinsic starts with tissue factor released from damaged tissue.
- Memorizing factor numbers without following the pathway logic, because students then miss that both branches converge at factor X and lead to the same common pathway.
- Thinking thrombin only makes fibrin, because thrombin also activates other clotting factors and strengthens the overall clotting response.
- Assuming PT and aPTT test completely separate systems, because both tests include the common pathway and can both be prolonged by defects in factors X, V, II, or fibrinogen.
Practice Questions
- 1 A patient has a deficiency of factor VIII. Which pathway is primarily affected, and would you expect PT or aPTT to be prolonged?
- 2 Factor Xa converts prothrombin to thrombin. If 12 units of prothrombin are converted and each unit yields 1 unit of thrombin, how many units of thrombin are produced?
- 3 A patient has normal factor VII but severe deficiency of factor X. Which parts of the cascade can still begin normally, and why will stable fibrin clot formation still be impaired?
- 4 Explain why both the intrinsic and extrinsic pathways are shown separately in diagrams even though they converge on the same common pathway in actual clot formation.